الفهرس 
Definitions related to sepsisOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
The available evidence suggests that, in the future, treatment of sepsis may benefit from including statin therapy.
Given their pleiotropic effects related to many pathophysiological determinants of sepsis, statin therapy may be the next logical step in the search for adjuvant therapy.
Although no potential randomised human trials testing the effects of statins in sepsis exist, a number of observational studies—the largest includes nearly 70 000 patients—point to a potential benefit.
It is also increasingly recognised that the proposed benefits of statins may be significant in other high-risk patient groups.
Examples include patients admitted to intensive care and those at high risk of developing organ failure caused by aggressive medical treatment.
Furthermore, it was recently suggested that statin therapy may represent a valuable adjuvant treatment for the expected influenza epidemic.
It is very important to test the efficacy and safety and the benefit/adverse effects of statins administered at the onset of sepsis, as well as in patients with severe sepsis or septic shock admitted into ICUs.
I has outlined various mechanisms by which statins directly and indirectly modulate many levels of the immune and inflammatory response associated with systemic inflammatory response syndrome and sepsis.
These mechanisms include effects on cell signalling with consequent changes at the transcriptional level, the induction of haem oxygenase, the direct alteration of leucocyte–endothelial cell interaction, and the reduced expression of MHC II.
Since statins do not target individual inflammatory mediators, but possibly reduce the overall magnitude of the systemic response, this effect may prove an important distinguishing feature modulating the host response to septic insults.
This work establishes the scientific view needed for future trials of statins in critical illness.